EP
SPRY icon

Essential Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Essential Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$134 Sell
31
-2
-6% -$12 ﹤0.01% 2661
2026
Q2 		$264 Sell
33
-41
-55% -$353 ﹤0.01% 2596
2026
Q1 		$594 Buy
74
+70
+1,750% +$671 ﹤0.01% 2383
2025
Q4 		$47 Buy
+4
New +$39 ﹤0.01% 2642
2025
Q3 		– Sell
-57
Closed -$995 – 2778
2025
Q2 		$995 Buy
+57
New +$822 ﹤0.01% 1520

Other funds holding SPRY

Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
NFGCM
Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return
CX Institutional
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
BLC
Brown, Lisle/Cummings Providence, Rhode Island $453M AUM 20.23% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's SPRY Position: Q3 2026 in Review

Essential Partners reduced its ARS Pharmaceuticals (SPRY) stake by 6.1% in Q3 2026, selling an estimated $12 and leaving 31 shares worth $134. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Essential Partners first reported a position in SPRY in Q2 2025 and has held it in 5 quarters since. The position peaked at $995 in Q2 2025. 12 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

  • Essential Partners held 31 shares of ARS Pharmaceuticals worth $134 as of Q3 2026.
  • Essential Partners sold 2 ARS Pharmaceuticals shares in Q3 2026, an estimated $12.
  • ARS Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2661 holding.
  • Essential Partners first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's ARS Pharmaceuticals position peaked at $995 in Q2 2025.
  • 12 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.